A new study published in JAMA found that using apoB to guide cholesterol-lowering therapy outperformed standard LDL and non-HDL cholesterol approaches in a simulated population of U.S. adults. Researchers determined the strategy would improve health outcomes while remaining cost-effective for the healthcare system.

What is ApoB?

ApoB counts the total number of harmful cholesterol-carrying particles in the blood. Each atherogenic particle contains one apoB molecule, providing a more direct measure of risk than tests that measure the amount of cholesterol within those particles.

According to the study lead author, Ciaran Kohli-Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine, “Research strongly shows that apolipoprotein B (apoB) is better at identifying who is at risk, because it counts the total number of harmful particles in the blood.”

The analysis used a computer simulation of 250,000 U.S. adults eligible for statin therapy but without existing cardiovascular disease. Researchers compared three strategies: LDL cholesterol targets below 100 mg/dL, non-HDL cholesterol targets below 118 mg/dL, and apoB targets below 78.7 mg/dL.

Findings and Implications

Over a lifetime horizon, the apoB-guided approach prevented more heart attacks and strokes, increased life expectancy and quality-adjusted life years, and proved cost-effective according to standard U.S. healthcare thresholds.

The findings arrive as updated guidelines from the American Heart Association and other organizations recommend earlier and more personalized cholesterol management for many patients. Accurate risk assessment grows increasingly important with more treatment options available.

Original reporting: The Dallas Express — read the source article.